Clal Biotechnology reported ILS-5.44M in EBIT for its fiscal quarter ending in December of 2022.





Ebit Change Date
aTyr Pharma USD -226.49K 140.85K Sep/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -7.89M 536K Sep/2025
RedHill Biopharma USD 2.69M 47.97M Jun/2023